PhysioAssist
PhysioAssist is a French medical device company that develops and distributes Simeox, a CE-marked Class 2a airway clearance device using proprietary pneumatic vibratory signal technology for patients with cystic fibrosis, COPD, bronchiectasis, and primary ciliary dyskinesia, sold via exclusive distributors in ~20 countries.
- Company typePrivate
- Founded2012
- HeadquartersAix-en-provence, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What PhysioAssist does
PhysioAssist SAS is a French private medical device company founded in 2012 in Aix-en-Provence, France, that has developed and commercializes the Simeox device, a Class 2a medical device for airway clearance in patients with chronic respiratory conditions. The device delivers a proprietary pneumatic vibratory signal during exhalation that liquefies bronchial mucus in under two seconds and transports it from distal airways toward central airways, addressing conditions including cystic fibrosis, COPD, bronchiectasis, and primary ciliary dyskinesia. The underlying technology was developed in partnership with the French National Centre for Scientific Research (CNRS) and the CRCM at Hôpital Nord in Marseille, with an ongoing research program on bronchial mucus rheology; PhysioAssist also maintains a Germany contact office in Miesbach.
The company sells Simeox as its core product through an exclusive country-level distributor network covering approximately 20 markets across Europe, the Middle East, Canada, Australia, and Thailand (including PARI Medical in the UK, Novus Medical in Canada, BMedical in Australia, MedicAir in Italy, HABEL in Austria, and BMEC.asia in Thailand). Revenue is generated via hardware sales of the device and required accessories (tubing, filter, mouthpiece), with pricing handled through a quote-based sales process; Simeox is prescription-based and typically reimbursed through national health systems. The company supports adoption through the free Simeox Academy online training platform for healthcare professionals, active participation in international respiratory conferences (ERS, ECFS), peer-reviewed clinical publications (including a 2023 first RCT in the Children journal), and patient association partnerships such as with Vaincre La Mucoviscidose.
PhysioAssist has obtained CE marking (March 2016), homecare use certification (2019) enabling independent patient use at home, and MDSAP certification (December 2021) covering the US, Canada, Brazil, Japan, and Australia. The company has raised approximately €6 million in a September 2017 Series B led by Mérieux Développement with Turenne Capital; no subsequent funding rounds are disclosed. The company operates with 11–50 employees and is led by Founder & CEO Adrien Mithralal, with Anne Reiser as Chairman and Ulrich Fell as General Manager.
PhysioAssist firmographics
Firmographics- Name
- PhysioAssist
- Legal name
- Physio-Assist SAS
- Website
- https://physioassist.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- PhysioAssist is a French medical device company that develops and distributes Simeox, a CE-marked Class 2a airway clearance device using proprietary pneumatic vibratory signal technology for patients with cystic fibrosis, COPD, bronchiectasis, and primary ciliary dyskinesia, sold via exclusive distributors in ~20 countries.
- Ownership category
- akta.pro rank
Where PhysioAssist is headquartered
LocationHeadquarters
- HQ city
- Aix-en-provence
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
PhysioAssist business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Simeox Medical Device Sales: PhysioAssist generates revenue from the sale of Simeox devices, a Class 2a medical device for airway clearance. The device is sold through exclusive distributor networks in various countries, directly to healthcare institutions, and to patients for home use following healthcare professional prescription and training.
- Accessories and Consumables: Specific accessories (tubing, filter, and mouthpiece) are required for use with Simeox device. The design of the filter is specific and contributes to the efficacy of the device.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Device pricing (quote-based) |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels7 records
PhysioAssist product offering
Product offeringCore offering
PhysioAssist designs, manufactures, and sells the Simeox device, a Class 2a medical device that delivers a proprietary pneumatic vibratory signal during exhalation to liquefy and mobilize bronchial mucus from distal airways in patients with chronic respiratory conditions (cystic fibrosis, COPD, bronchiectasis, primary ciliary dyskinesia). The company also operates the Simeox Academy, a free online training platform that educates healthcare professionals on device handling and clinical use. Revenue is generated primarily through hardware sales of the Simeox device and its dedicated consumables (tubing, filter, mouthpiece) via an exclusive international distributor network.
Product overview
PhysioAssist offers a focused product portfolio centered on the Simeox airway clearance medical device. The core offering is the Simeox device, a Class 2a CE-marked medical device that uses proprietary pneumatic signal technology to liquefy and mobilize bronchial mucus in patients with chronic respiratory diseases. This is supported by the Simeox Academy online training platform, which provides healthcare professionals with comprehensive education on device usage and clinical applications. The company operates through a network of exclusive international distributors across Europe, Middle East, Canada, Australia, and Asia.
Differentiator
Problem solved
Functional benefit
Products and services
- Simeox Simeox is a Class 2a medical device that delivers a specific pneumatic vibratory signal during exhalation to liquefy bronchial mucus and transport it from distal to central airways. It is designed for patients with chronic respiratory conditions including cystic fibrosis, COPD, bronchiectasis, and Primary Ciliary Dyskinesia, and can be used in clinical settings or autonomously at home after training by a healthcare professional.
- Simeox Academy Simeox Academy is a free online training platform for healthcare professionals that provides theoretical and practical instruction on the Simeox device, including pathophysiology of mucus clearance, device handling, and clinical practice with real patient demonstrations.
Quantifiable outcome
- In children with cystic fibrosis: Significantly decreased lung obstruction, preserved global ventilation homogeneity especially of distal tract (LCI), increased quality of life (functional physical capacity), safe with no adverse effects
- +4 more outcomes
Companies that use PhysioAssist
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles2 records
PhysioAssist technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
PhysioAssist partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered flagship, core and regional.
- Vaincre La MucoviscidoseflagshipPartnership with French CF patient association to facilitate access to Simeox device at home without engagement, including financial assistance to patients who wish to access the device.
- Novus Medical Inc.coreExclusive distributor for Canada market, helping respiratory clinicians improve patient lives through access to Simeox device.
- PARI Medical Ltd.coreExclusive distribution agreement for the UK territory. PARI's mission is to improve lives of those affected by respiratory diseases through their portfolio of innovative products and services.
- CNRS (Centre National de la Recherche Scientifique)coreResearch partnership for the study of bronchial mucus and development of pneumatic vibratory signal technology present in Simeox device. Collaboration with CRCM Hôpital Nord Marseille.
- CRCM Hôpital Nord MarseillecoreResources and Competences Center for Cystic Fibrosis collaborated with PhysioAssist and CNRS on airway clearance research and Simeox technology development.
- BMEC.asiaregionalDistribution partner for Thailand market, led by Medha Namjoshi.
Scale indicators3 records
Recent moves8 records
Expansion highlights7 records
PhysioAssist competitors and assessment
Company assessmentDirect peers
- PARI Medical Holding: PARI is both an exclusive UK distributor of Simeox and a direct competitor with its own airway clearance portfolio including the PARI O-PEP and eFlow respiratory nebulizer systems. Highly comparable as both a channel partner and a competing device maker in the same therapeutic niche.
- Trudell Medical International (Monaghan Medical): Makes the Acapella and Aerobika oscillating positive expiratory pressure (PEP) devices used for airway clearance in CF, COPD, and bronchiectasis — direct therapeutic alternatives to Simeox with overlapping patient populations and prescriber base (respiratory therapists and pulmonologists).
- Vyaire Medical: Vyaire (formerly CareFusion/BD respiratory) markets The Vest and MetaNeb systems for high-frequency chest wall oscillation (HFCWO) and continuous high-frequency oscillation (CHFO) airway clearance. Most established competitor in the institutional airway clearance market.
Broad incumbents
- Philips Respironics: Broad incumbent in respiratory care with nebulizers, ventilators, and airway clearance adjuncts. While not focused exclusively on mucus clearance, Philips competes for hospital respiratory therapy budgets and prescriber mindshare with Simeox.
- ResMed: Global leader in respiratory and sleep medicine devices including ventilation and COPD management solutions. ResMed's commercial scale, direct-to-clinician sales channels, and reimbursement expertise represent both a competitive threat and a potential strategic acquirer profile for PhysioAssist.
- Hillrom (now part of Baxter): Hillrom's The Vest System is one of the most widely adopted HFCWO airway clearance devices globally. As part of Baxter, the combined entity competes head-to-head with Simeox in CF centers and respiratory clinics worldwide.
- Drägerwerk: German medical device incumbent producing ventilators, anesthesia equipment, and respiratory therapy devices. Operates in the same hospital respiratory care channel as PhysioAssist and competes for ICU/pulmonology capex.
- Fisher & Paykel Healthcare: New Zealand-based respiratory care company with strong presence in humidification, CPAP, and COPD-adjacent devices. Comparable as a respiratory-focused medical device company with international distributor networks and recurring consumables.
- Smiths Medical: Major medical device company with respiratory care portfolio including airway management and humidification products. Comparable as a broad respiratory device incumbent competing for hospital and homecare channels relevant to Simeox.
Emerging players
- Vortran Medical Technology: Smaller medical device maker focused on disposable respiratory products including percussionators and oxygen delivery. Comparable niche-scale competitor in the respiratory therapy space with overlapping clinical use cases.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
PhysioAssist social profiles
Digital presencePhysioAssist compliance and trust
Trust signalCompliance2 records
PhysioAssist financial estimates
Financial estimateRevenue estimate
Valuation estimate
PhysioAssist leadership team
Management profileNumber of profiles
Profiles7 records
PhysioAssist funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PhysioAssist M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PhysioAssist
What does PhysioAssist do?
PhysioAssist designs, manufactures, and sells the Simeox device, a Class 2a medical device that delivers a proprietary pneumatic vibratory signal during exhalation to liquefy and mobilize bronchial mucus from distal airways in patients with chronic respiratory conditions (cystic fibrosis, COPD, bronchiectasis, primary ciliary dyskinesia). The company also operates the Simeox Academy, a free online training platform that educates healthcare professionals on device handling and clinical use. Revenue is generated primarily through hardware sales of the Simeox device and its dedicated consumables (tubing, filter, mouthpiece) via an exclusive international distributor network.
Is PhysioAssist a public or private company?
PhysioAssist is a private company. It is classified as venture growth investor backed and is currently operating.
When was PhysioAssist founded?
PhysioAssist was founded in 2012. It employs 11 to 50 people.
Where is PhysioAssist based?
PhysioAssist is headquartered in Aix-en-provence, France, in the Europe region.
How does PhysioAssist make money?
Two revenue lines are on record. Simeox Medical Device Sales are the primary driver. The others are accessories and Consumables.
Who are PhysioAssist's main competitors?
Direct peers on record are PARI Medical Holding, Trudell Medical International (Monaghan Medical) and Vyaire Medical. Broad incumbents are Philips Respironics, ResMed, Hillrom (now part of Baxter), Drägerwerk, Fisher & Paykel Healthcare and Smiths Medical. Vortran Medical Technology is listed as an emerging player.
Does PhysioAssist have an API?
No public API is recorded for PhysioAssist.